novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

PCSK9 Inhibitors. A new avenue to reduce major vascular events – Xavier Garcia Moll

16 Agosto 2017

Resumo da apresentação

Apresentação

Xavier Garcia Moll
SP

Clinical trials in 2017 - João Morais

16 Agosto 2017
0

The role of devices to help patients with heart failure - Pedro Marques

23 Agosto 2017
0

-->